See more : Sonocom Co.,Ltd. (7902.T) Income Statement Analysis – Financial Results
Complete financial analysis of Relay Therapeutics, Inc. (RLAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Relay Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Fox Factory Holding Corp. (FOXF) Income Statement Analysis – Financial Results
- Netgem SA (ALNTG.PA) Income Statement Analysis – Financial Results
- PP Capital – Tactical Asset Allocation (PMICTAAKLNEUR.CO) Income Statement Analysis – Financial Results
- Natural Health Trends Corp. (NHTC) Income Statement Analysis – Financial Results
- Cyprium Metals Limited (CYM.AX) Income Statement Analysis – Financial Results
Relay Therapeutics, Inc. (RLAY)
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 25.55M | 1.38M | 3.03M | 82.65M | 0.00 | 0.00 |
| Cost of Revenue | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| Gross Profit | 20.28M | -2.75M | -896.00K | 79.11M | -2.85M | -2.15M |
| Gross Profit Ratio | 79.37% | -199.06% | -29.58% | 95.71% | 0.00% | 0.00% |
| Research & Development | 330.02M | 246.36M | 172.65M | 99.86M | 70.31M | 41.03M |
| General & Administrative | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.95M | 65.98M | 57.39M | 38.59M | 13.74M | 8.86M |
| Other Expenses | 0.00 | -20.00K | -4.00K | -16.00K | -58.00K | -9.00K |
| Operating Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Cost & Expenses | 398.55M | 312.33M | 230.04M | 138.45M | 84.05M | 49.89M |
| Interest Income | 31.05M | 8.79M | 830.00K | 3.40M | 8.80M | 1.11M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.27M | 4.13M | 3.93M | 3.55M | 2.85M | 2.15M |
| EBITDA | -374.15M | -306.82M | -222.18M | -52.25M | -81.20M | -47.74M |
| EBITDA Ratio | -1,464.62% | -23,361.98% | -2,948.70% | -63.21% | 0.00% | 0.00% |
| Operating Income | -373.00M | -299.28M | -364.70M | -55.80M | -84.05M | -49.89M |
| Operating Income Ratio | -1,460.11% | -21,670.89% | -12,040.21% | -67.51% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.03M | 8.77M | 826.00K | 3.38M | 8.74M | 1.10M |
| Income Before Tax | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.79M |
| Income Before Tax Ratio | -1,338.66% | -21,036.13% | -12,012.94% | -63.41% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -36.25M | 132.94M | -3.40M | -8.80M | 1.10M |
| Net Income | -341.97M | -254.26M | -496.81M | -49.01M | -66.50M | -48.79M |
| Net Income Ratio | -1,338.66% | -18,411.22% | -16,401.72% | -59.30% | 0.00% | 0.00% |
| EPS | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| EPS Diluted | -2.79 | -2.27 | -5.22 | -1.15 | -15.53 | -19.63 |
| Weighted Avg Shares Out | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
| Weighted Avg Shares Out (Dil) | 122.58M | 112.23M | 95.14M | 42.62M | 4.28M | 2.49M |
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Misses Revenue Estimates
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics, Inc. (RLAY) Surges 13.8%: Is This an Indication of Further Gains?
Source: https://incomestatements.info
Category: Stock Reports